Comment on Keeler et al. Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. Nutrients 2021, 13, 4158

Abstract

Anorexia Nervosa (AN) represents a difficult therapeutic challenge, with up to 4% prevalence among females and increasing incidence among youth [...]

Reply to Skokou, M. Comment on “Keeler et al. Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. Nutrients 2021, 13, 4158”

“…Taken together, we agree with Skokou [ 2 ] that the glutamate system might be highly relevant for the treatment of eating disorders. As explained in our previous paper [ 1 ], we particularly believe that ketamine might lead to a breakthrough in the pharmacological treatment of AN.…”

“…In response to our narrative review, which suggested the use of the glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist ketamine as a potential treatment for anorexia nervosa (AN) [ 1 ], Maria Skokou posed the question whether other glutamatergic medications (e.g., lamotrigine) might be effective in the treatment of eating disorders in general [ 2 ]. Therefore, we would like to develop the idea further that the glutamate system might be of relevance for the pathophysiology and the treatment of eating disorders.…”

“…Skokou [ 2 ] already mentioned the small case series which tested lamotrigine in people with bulimia nervosa (BN) [ 13 , 14 ], where lamotrigine treatment was associated with reductions in eating disorder symptoms. People with BN often experience problems with their mood, affect and impulsiveness.…”